Cambridge Epigenetix (CEGX), a spin-out from Cambridge University, has announced the completion of a $21m Series B round led by GV (formerly Google Ventures) with participation from Sequoia Capital, New Science Ventures, Syncona Partners and Cambridge University.
CEGX produces DNA modification analysis tools for epigenetics researchers. Epigenetics is the study of how environmental and behavioral factors can “regulate gene expression” rather than changing the underlying DNA and result in heritable traits.
The funding will be used to finance ongoing research and development of new epigenetics technologies and capitalise on a wider set of applications in life sciences.
Dr. Yerramilli-Rao, co-founder of CEGX, said: “CEGX’s mission is to promote better health through continuous measurement of the epigenome. CEGX’s novel technologies are allowing scientists to begin unlocking the tremendous potential of epigenetics.”
Tom Hulme, GV general partner, commented: “We’ve seen how the commercialisation of genome sequencing has created incredible opportunities to improve human health, and now the epigenome holds similar potential.
“Cambridge Epigenetix is one of the few teams on the planet with the skills and experience to break new ground here, and we look forward to supporting them on that journey.”